12/16/2025 09:00
Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments
Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring paymen...
12/18/2025 16:00
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering
Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218764112/en/Image courtesy of Neural Concept (L-R clock...
‘‘Discovering past icons’’, AFP’s photographic heritage in the spotlight in Paris this autumn
From October 26 to November 5, 2022, Ellia Art Gallery will be exhibiting in the Marais district of Paris 200 collector’s prints from the photo archives of AFP, the world’s oldest news agency. The agency is offering visitors an exceptional selection, sometimes iconic, sometimes unpublished, which at the end of the exhibition will be auctioned off in the gallery itself by Elsa Joly-Malhomme (Ader Entreprises & Patrimoine, expert: Antoine Romand) and on drouot.com.
Anglais
11/13/2025 06:00
Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines
Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced the completion of a $15 million financing round from existing shareholders. The funds will support continued clinical and development activities for V-212, Virometix’s lead serotype-independent pneumococcal vaccine candidate, currently in Phase I clinical evaluation. Proceeds from the financing will be used to: Advance the ongoing Phase I clinical trial of V-212, with topline results e...